Crohn's Disease

Among a large cohort of patients with psoriasis, researchers found around 20% had an immune-mediated inflammatory disease develop before psoriasis onset and 14% had one develop after psoriasis onset, according to a study using data from the Danish National Patient Registry.

Patients with inflammatory bowel disease who received long-duration vancomycin as treatment for Clostridioides difficile infection had lower recurrence rates compared with patients who receive shorter durations of the drug, according to study results.

Patients with Crohn’s disease who achieved complete mucosal healing experienced better outcomes than those who just had partial healing, according to study results.

AVA,Dx, a machine learning method for risk prediction of Crohn’s disease, revealed new potential CD genes and accurately identified the disease in a group of more than 3,000 individuals, according to a recent study.

SAN ANTONIO — Researchers were able to identify predictors of response to Stelara in Crohn’s disease, and subsequently model those predictors into a decision-support tool model that helped predict both achievement of clinical remission and rapidity with which symptoms reduced.

The FDA has selected the Crohn’s & Colitis Foundation as one of just two patient organizations that will take part in its Real-World Evidence Program using the MyStudies App, which will allow the foundation to expand research and data systems, according to a press release.

In the United Kingdom, the prevalence of inflammatory bowel disease has increased significantly since 2000 and is expected to keep rising, according to study results presented at UEG Week.

Phase 3 trial results indicated the oral antibiotic known as RHB-104 led to durable clinical remission in patients with Crohn’s disease, and a recent study showed that fecal microbiota transplantation lowered mortality in patients with severe and fulminant Clostridioides difficile infection

Two advancements in eosinophilic esophagitis — the success of the biologic therapy Dupixent in reducing symptoms and improving quality-of life, and the accuracy of a minimally invasive diagnostic test in distinguishing active vs. inactive disease — were among the stop stories in gastroenterology last week.

RHB-104, an oral antibiotic, appeared safe and effective for the treatment of Crohn’s disease, according to the manufacturer.